Al-hijamah (wet cupping therapy of prophetic medicine) significantly and safely reduces iron overload and oxidative stress in thalassemic children: a novel pilot study
| Autor: | Hamdi H. Almaramhy, Amal Albeihany, Mohamed Attia, Hussam Baghdadi, Salah Mohamed El Sayed, Hoda Ali Ibrahim, Amr El-Dardear, Mongi Ayat, Manal Mohamed Helmy Nabo, Yasmin Shebl, Mohamed El-Shanshory, Ahmed Ragab Fakhreldin, Hany Salah Mahmoud, Nahed Mohammed Hablas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
thalassemia
medicine.medical_specialty iron chelation therapy medicine.medical_treatment Thalassemia clearance medicine.disease_cause Gastroenterology Al-hijamah indices Excretion Journal of Blood Medicine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Hemofiltration oxidative stress Medicine Decreased serum ferritin Dialysis business.industry Hematology medicine.disease Malondialdehyde Al-hijamah Clinical trial chemistry Clinical Trial Report 030220 oncology & carcinogenesis business 030217 neurology & neurosurgery Oxidative stress |
| Zdroj: | Journal of Blood Medicine |
| ISSN: | 1179-2736 |
| Popis: | Background Thalassemia is a major health problem due to iron overload, iron deposition and oxidative stress-induced tissue damage. Here, we introduce Al-hijamah (a minor surgical excretory procedure) as a novel percutaneous iron excretion therapy. Al-hijamah is a wet cupping therapy of prophetic medicine, and prophet Muhammad, peace be upon him, strongly recommended Al-hijamah, saying: “The best of your treatment is Al-hijamah”. Aim of the study Our study aimed at investigating the safety, iron chelation, pharmacological potentiation and oxidant clearance effects exerted by Al-hijamah to thalassemic children. Patients and methods Ethical committee’s approval and patients’ written agreement consents were obtained. We treated 20 thalassemic children (15 males and five females aged 9.07±4.26 years) with iron chelation therapy (ICT) plus Al-hijamah (using sterile disposable sets and in a complete aseptic environment) vs a control group treated with ICT only. This clinical trial was registered in the ClinicalTrial.gov registry under the name “Study of the Therapeutic Benefits of Al-hijamah in Children with Beta Thalassemia Major” (identifier no NCT 02761395) on 30 January 2016. Results Al-hijamah was quite simple, safe, effective, tolerable (with no side effects) and time-saving procedure (30–60 minutes). A single session of Al-hijamah significantly reduced iron overload (P Video abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|